Caplight Directory>Companies>Chromatin Bioscience-preview>Chromatinbio


Chromatin Bioscience

Chromatin Bioscience

Private
EdinburghN/Ahttps://www.chromatinbio.com/

Last Round

Grant

Jan 6, 2026

Total Funding Raised

$130,000

Company Overview

Chromatin Bioscience is a biotechnology company that provides a platform for designing and developing synthetic promoters for cell-type selective gene expression.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Chromatin Bioscience Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Chromatin Bioscience Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantJan 6, 2026
GrantOct 4, 2024
View all Funding Rounds

Key People

Founding team and executive leadership

Michael Roberts

Founder & CEO

Founding Team

Chromatin Bioscience Investors

Notable investors and investment history

InvestorRounds
UKRI Innovate UKGrant
National Research Council Canada Industrial Research Assistance ProgramGrant
Scottish Investment Bank (Scottish Enterprise)Grant
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    Monthly visitors increased 70% MoM.

  • Jan 6, 2026

    Received funding from National Research Council of Canada and UKRI Innovate UK.

View all signals

Chromatin Bioscience Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Chromatin Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Chromatin Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdinburgh
Employee Range6
Year Founded2022
Last FundingJan 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.